Back to Search
Start Over
Impact of empagliflozin on first and recurrent events leading to or prolonging hospitalisation in the EMPA-REG OUTCOME trial.
- Source :
-
Diabetes Research & Clinical Practice . Jun2024, Vol. 212, pN.PAG-N.PAG. 1p. - Publication Year :
- 2024
-
Abstract
- In EMPA-REG OUTCOME, empagliflozin reduced the composite of total events leading to/prolonging hospitalisation for any cause and all-cause mortality by 24 % versus placebo in patients with T2DM and ASCVD, with 67.7 events prevented/1000 patient-years and a low NNT. Effects were sustained and were consistent regardless of the reason for hospitalisation. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 01688227
- Volume :
- 212
- Database :
- Academic Search Index
- Journal :
- Diabetes Research & Clinical Practice
- Publication Type :
- Academic Journal
- Accession number :
- 177756791
- Full Text :
- https://doi.org/10.1016/j.diabres.2024.111715